Search Result

Results for "

786-O

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Antibiotic (2) Apoptosis (7) Autophagy (5) Bacterial (2) BCRP (4) c-Kit (5) Casein Kinase (2) DAPK (1) Dopamine Receptor (3) Ferroptosis (3) FGFR (5) GLUT (1) Glutathione Peroxidase (1) HIF/HIF Prolyl-Hydroxylase (7) Histone Demethylase (1) HSP (1) Isocitrate Dehydrogenase (IDH) (1) JNK (3) MDM-2/p53 (1) Microtubule/Tubulin (1) Nuclear Hormone Receptor 4A/NR4A (2) P-glycoprotein (4) p38 MAPK (3) PDGFR (5) PERK (3) Raf (5) Reactive Oxygen Species (ROS) (3) Reference Standards (4) RET (5) ROR (1) Tie (5) Transmembrane Glycoprotein (1) VEGFR (5) γ-Glutamyl Transferase (GGT) (1)
By Research Areas:	Cancer (34) Cardiovascular Disease (4) Infection (3) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (1)

By Targets:

ADC Payload (1)

Antibiotic (2)

Apoptosis (7)

Autophagy (5)

Bacterial (2)

BCRP (4)

c-Kit (5)

Casein Kinase (2)

DAPK (1)

Dopamine Receptor (3)

Ferroptosis (3)

FGFR (5)

GLUT (1)

Glutathione Peroxidase (1)

HIF/HIF Prolyl-Hydroxylase (7)

Histone Demethylase (1)

HSP (1)

Isocitrate Dehydrogenase (IDH) (1)

JNK (3)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Nuclear Hormone Receptor 4A/NR4A (2)

P-glycoprotein (4)

p38 MAPK (3)

PDGFR (5)

PERK (3)

Raf (5)

Reactive Oxygen Species (ROS) (3)

Reference Standards (4)

RET (5)

ROR (1)

Tie (5)

Transmembrane Glycoprotein (1)

VEGFR (5)

γ-Glutamyl Transferase (GGT) (1)

By Research Areas:

Cancer (34)

Cardiovascular Disease (4)

Infection (3)

Inflammation/Immunology (1)

Metabolic Disease (4)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161096

Antitumor agent-127	ROR	Cancer
Antitumor agent-127 (compound 1) is a parent macrocyclic peptide. Antitumor agent-127 displays nanomolar cell-based binding to ROR1 and relatively good internalization in 786-O and MDA-MB-231 tumor cell lines .

HY-145835

PERK-IN-5	PERK	Cancer
PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC₅₀s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model .

HY-112055

DIM-C-pPhOH 5+ Cited Publications	Nuclear Hormone Receptor 4A/NR4A Apoptosis	Cancer
DIM-C-pPhOH is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhOH inhibits cancer cell growth and mTOR signaling, induce apoptosis and cellular stress. DIM-C-pPhOH reduces cell proliferation with IC50 values of 13.6 μM and 13.0 μM for ACHN cells and 786-O cells, respectively .

HY-153016

HIF-2α agonist 2	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
HIF-2α agonist 2 (compound 10) is a HIF-2α agonist with an EC₅₀ value of 1.68 μM at the dose of 20 μM. HIF-2α agonist 2 is non-cytotoxic against 786-O-HRE-Luc cells. HIF-2α agonist 2 can be used for oxygen metabolism research .

HY-176508

KDX1381	Casein Kinase	Cancer
KDX1381 is a bivalent CK2α inhibitor (IC₅₀: 17 nM, K_D: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .

HY-170675

Ferroptosis-IN-13	Ferroptosis	Cancer
Ferroptosis-IN-13 (compound NY-26) is a ferroptosis inhibitor. Ferroptosis-IN-13 inhibits RSL3(HY-100218A)-induced ferroptosis in 786-O cells with an EC₅₀ value of 62 nM .

HY-169298

Ferroptosis-IN-15	Ferroptosis	Cancer
Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC₅₀s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .

HY-168707

CK2-IN-14	Casein Kinase	Cancer
CK2-IN-14 (Compound 10b) is an inhibitor for cyclin kinase 2α with an IC₅₀ of 36.7 nM. CK2-IN-14 inhibits the growth of cancer cell 786-O and U937 with GI₅₀ of 7.3 μM and 7.5 μM .

HY-170959

NYY-6a	Ferroptosis	Neurological Disease Metabolic Disease
NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC₅₀s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .

HY-149388

Anticancer agent 139	Microtubule/Tubulin	Cancer
Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a π–cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-P10221A

Cyclo(CKLIIF) TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 2.6 and 2.2 μM, respectively .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-126710

OU749	γ-Glutamyl Transferase (GGT)	Cancer
OU749 is a potent γ-glutamyl transpeptidase (GGT) inhibitor with a K_i value of 17.6 µM. OU749 shows cytotoxicity .

HY-50879R

Elacridar (Standard)	P-glycoprotein BCRP	Cancer
Elacridar (Standard) is the analytical standard of Elacridar. This product is intended for research and analytical applications. Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .

HY-139287

M1002 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .

HY-50880

Elacridar hydrochloride 25+ Cited Publications GF120918A	P-glycoprotein BCRP	Cancer
Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer .

HY-111547

M1001	HIF/HIF Prolyl-Hydroxylase	Cancer
M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a K_d of 667 nM. M1001 can be used in chronic kidney disease research .

HY-50880R

Elacridar hydrochloride (Standard)	P-glycoprotein BCRP	Cancer
Elacridar (hydrochloride) (Standard) is the analytical standard of Elacridar (hydrochloride). This product is intended for research and analytical applications. Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer .

HY-138556

GPX4-IN-2	Glutathione Peroxidase	Cancer
GPX4-IN-2 is a potent GPX4 inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-2 has the potential for the research of cancer .

HY-50879

Elacridar 25+ Cited Publications GF120918; GW0918; GG918; GW120918	P-glycoprotein BCRP	Cancer
Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .

HY-146420

GRP78-IN-2	HSP	Cardiovascular Disease Cancer
GRP78-IN-2 (Compound FL5) is a GRP78 (Glucose Regulated Protein 78 kDa) inhibitor. GRP78-IN-2 preferentially targeting cell surface GRP78 and shows potent antiangiogenic and anticancer activities without affecting other normal cells .

HY-P2324

Gramicidin A 1 Publications Verification	Bacterial HIF/HIF Prolyl-Hydroxylase Antibiotic	Infection Cancer
Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α) .

HY-P2324A

Gramicidin A TFA	Antibiotic Bacterial	Infection
Gramicidin A (TFA) is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A (TFA) is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A (TFA) induces degradation of hypoxia inducible factor 1 α (HIF-1α) .

HY-110021

Fenoldopam hydrochloride SKF 82526 hydrochloride	Dopamine Receptor Histone Demethylase Apoptosis	Cardiovascular Disease Cancer
Fenoldopam (SKF 82526) hydrochloride is a D₁ receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC₅₀=0.8974 μM). Fenoldopam hydrochloride shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-112780

UC2288 5 Publications Verification	MDM-2/p53 Apoptosis	Cancer
UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM .

HY-145835A

(S)-PERK-IN-5	PERK	Infection Cancer
(S)-PERK-IN-5 is the S-enantiomer of PERK-IN-5. (S)-PERK-IN-5 (example 39) is a PERK inhibitor, with an IC₅₀ of 0.101-0.250 μM .

HY-112056

DIM-C-pPhCO2Me 1 Publications Verification	Nuclear Hormone Receptor 4A/NR4A Apoptosis DAPK Isocitrate Dehydrogenase (IDH) PERK	Cancer
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .

HY-111431

p-Cresyl sulfate 5 Publications Verification p-Tolyl sulfate	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .

HY-111431AR

p-Cresyl sulfate potassium (Standard)	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways .

HY-111431R

p-Cresyl sulfate (Standard) p-Tolyl sulfate (Standard)	Reference Standards JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
Platycodin D (Standard) is the analytical standard of Platycodin D. This product is intended for research and analytical applications. Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .

HY-165245

SBI-183	Transmembrane Glycoprotein	Cancer
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-10331R

Regorafenib (Standard) BAY 73-4506 (Standard)	Reference Standards VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331

Regorafenib Maximum Cited Publications 67 Publications Verification BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331AR

Regorafenib monohydrate (Standard) BAY 73-4506 monohydrate (Standard)	Reference Standards VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-B0735A

Fenoldopam mesylate 4 Publications Verification Fenoldopam methanesulfonate; SKF-82526 mesylate	Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam mesylate (SKF-82526) is a D₁ receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC₅₀=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-10331B

Regorafenib mesylate BAY 73-4506 mesylate	VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie	Cancer
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .

HY-B0735AR

Fenoldopam mesylate (Standard) Fenoldopam methanesulfonate (Standard); SKF-82526 mesylate (Standard)	Reference Standards Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam (mesylate) (Standard) is the analytical standard of Fenoldopam (mesylate). This product is intended for research and analytical applications. Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-10331A

Regorafenib monohydrate Maximum Cited Publications 67 Publications Verification BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-133541

Glucopiericidin A	GLUT ADC Payload Apoptosis	Cancer
Glucopiericidin A is a natural piericidin compound obtained from a marine-derived Streptomyces strain. Glucopiericidin A serves as a glucose transporter (GLUT) chemical probe and suppresses glycolysis. Glucopiericidin A inhibits ATP-dependent filopodia protrusion with Piericidin A (PA; HY-114936) and has no effect alone. Glucopiericidin A induces cell apoptosis through reducing the reactive oxygen species (ROS) level by increasing PRDX1 and exhibits potent antitumor efficacy in ACHN mice xenografts .

Cat. No.	Product Name	Target	Research Area